No regulatory pipeline accelerates faster than the direct threat of a lethal, uncontained pathogen.
During high-mortality epidemics, international organizations and local researchers bypass traditional administrative and logistical timelines to deploy clinical trials.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The immediate threat of a highly lethal, person-to-person hantavirus pathogen prompted the federal government to bypass standard regulatory delays to deploy investigational medical countermeasures.
A rapid infestation of an animal-threatening, flesh-eating parasite triggered emergency movement controls, multi-state quarantines, and direct activation of emergency response infrastructure.
With 4,444 dead and no approved Bundibugyo vaccine or treatment, first-in-human dosing is being deployed directly into the uncontained lethal epidemic.
Under the threat of a rapidly expanding Ebola epidemic, global health authorities bypassed standard timelines to let an existing vaccine leapfrog directly into a Phase III trial.
The active, high-mortality Ebola outbreak forced global health organizations to rapidly deploy a Phase III trial inside the active transmission zone.
The severity and rapid growth of the Bundibugyo Ebola outbreak forced the immediate launch of unprecedented vaccine and therapeutic clinical trials.